SCHEMBL3524969

SCHEMBL3524969

CS(=O)(=O)c1nccc(-c2c(-c3ccc(F)cc3)nc3c(N)nccn23)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 6/20 0.71
CCNA2 P20248 2/20 0.71
CDK2 P24941 2/20 0.71
CDK5 Q00535 2/20 0.71
CDK5R1 Q15078 2/20 0.71
CCNT1 O60563 1/20 0.71
CDK9 P50750 1/20 0.71
HASPIN Q8TF76 1/20 0.71
GRIA1 P42261 3/20 0.53
MAPK9 P45984 5/20 0.47
CSNK1D P48730 5/20 0.47
PRKD2 Q9BZL6 4/20 0.47
RPS6KA3 P51812 1/20 0.47
LIMK1 P53667 1/20 0.47
DYRK1A Q13627 1/20 0.47
MAPK14 Q16539 1/20 0.47
PRKD3 O94806 3/20 0.47
MAP4K4 O95819 3/20 0.47
CSNK1A1 P48729 3/20 0.47
CSNK1G2 P78368 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519701 0.89 MAPK9 (0.58) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3522612 0.88 MAPK9 (0.58) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3525694 0.86 CSNK1E (0.71) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3519582 0.84 CSNK1E (0.50) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3523791 0.83 MAPK9 (0.51) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3523115 0.83 CSNK1E (0.49) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3525223 0.83 GRIA1 (0.55) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL14600037 0.82 CSNK1E (0.48) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3520134 0.82 CSNK1E (0.48) CSNK1ECCNA2CDK2CDK5CDK5R1
SCHEMBL3521273 0.82 MAPK9 (0.62) CSNK1ECCNA2CDK2CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709468-B2 Imidazo based heterocycles ABBOTT LABORATORIES (US) 2010-05-04 US disclosed
EP-1928237-A2 NOVEL IMIDAZO BASED HETEROCYCLES Abbott Laboratories (US) 2008-06-11 EP disclosed
US-20070099925-A1 Novel imidazo based heterocycles ABBVIE INC. 2007-05-03 US disclosed
WO-2007028051-A2 NOVEL IMIDAZO BASED HETEROCYCLES ABBOTT LABORATORIES (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099925-A1 Novel imidazo based heterocycles CDK4, CDK2, MAP3K19 CSNK1E 216/4885CCNA2 208/4885CDK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.